Drug Evaluation Committee We Have Published a Paper on the JPMA’s Perspective Regarding the FDA Roadmap and Related Documents

We have published a paper presenting the results of a survey conducted by the JPMA among its member companies in July 2025 regarding the FDA Roadmap and New Approach Methodologies (NAMs), along with recommendations based on those results. Please refer to it.

Impact of the FDA Roadmap and Perspectives for Regulatory Use of New Approach Methodologies in Japanese Pharmaceutical Companies

Back to All Communications

TOP